The Breast Journal[JOURNAL]
Sun
200 papers
Life Postdiagnosis: Female Adult Breast Cancer Survivors' Experience With Physical Activity-A Qualitative Systematic Review.
Brown N, Muirhead F
Breast J · 2025 · PMID 41048369 · Full text
With increasing survival rates of breast cancer, there is a need for more research to understand the experiences of survivors. Previous quantitative studies have shown that physical activity can be beneficial for breast...
With increasing survival rates of breast cancer, there is a need for more research to understand the experiences of survivors. Previous quantitative studies have shown that physical activity can be beneficial for breast cancer survivors. However, a qualitative perspective is essential to create appropriate adaptations for this population. This study aims to develop a deeper understanding of the experiences of female adult breast cancer survivors with physical activity in their postdiagnosis lifestyle. This study followed a qualitative systematic review methodology. In January 2024, six databases (APA PsycInfo, CINAHL Plus, OVID Medline, Scopus, SPORTDiscus and Sports Medicine an Education Index) were searched using aim-specific key terms. Ten studies, comprising a total sample of 200 participants, met the inclusion criteria. Quality appraisal, data extraction and synthesis stages were conducted. Five main themes emerged during the synthesis stage: (1) Outcomes of Physical Activity Participation, (2) Barriers to Physical Activity, (3) Postdiagnosis Balancing Act, (4) Needs for Future Physical Activity Programs and (5) Next Steps for Breast Cancer Survivors. Additionally, 15 subthemes were identified. Overall, breast cancer survivors reported positive experiences with physical activity, leading to a desire to maintain an active lifestyle. However, barriers such as treatment side effects, unmet needs for advice from health services and challenges in daily life postdiagnosis were identified. Future research should explore the implementation of specific national guidelines and recommendations for survivors postdiagnosis to overcome these barriers and enhance the quality of survivorship care.
Skin Involvement of Idiopathic Granulomatous Mastitis: Sonographic, Clinical, and Histopathological Features.
Işık F, Pala E, Alper F … +4 more , Ozmen S, Demirci E, Abbasguliyev H, Akçay MN
Breast J · 2025 · PMID 41041149 · Full text
Idiopathic granulomatous mastitis (IGM) is a rare benign breast disease in which cutaneous involvement is insufficiently characterized. This study aimed to evaluate the sonographic, clinical, and histopathological featur...
Idiopathic granulomatous mastitis (IGM) is a rare benign breast disease in which cutaneous involvement is insufficiently characterized. This study aimed to evaluate the sonographic, clinical, and histopathological features of skin manifestations in IGM. We retrospectively analyzed 138 women with biopsy-proven IGM who underwent breast and skin ultrasonography between 2023 and 2024. Clinical cutaneous findings were documented, and 14 patients with visible skin lesions underwent additional punch biopsy for histopathological evaluation. Sonographic and clinical features were stratified according to symptom duration (0-3, 4-6, 7-9, and ≥ 10 weeks). Cutaneous lesions were identified in 84/138 patients (60.9%). Sonographic findings followed a sequential distribution: fibrous echogenicity loss in early disease (11/14, 78.6%), vacuolar structures at 4-6 weeks (11/19, 57.9%), dermo-subcutaneous blurring at 7-9 weeks (9/34, 26.5%), and advanced features such as fistula formation (11/17, 64.7%) and dermo-subcutaneous disruption (11/17, 64.7%) beyond 10 weeks. Clinical findings paralleled imaging, with erythema and papulopustular lesions predominating early (13/14, 92.9%), erythema nodosum peaking at 4-6 weeks (7/19, 36.8%), and ulceration and fistula formation emerging after ≥ 7 weeks (11/17, 64.7% at ≥ 10 weeks). Histopathological analysis of 14 skin biopsies demonstrated nonspecific inflammatory changes without granuloma formation. IGM demonstrates sequential sonographic and clinical cutaneous patterns associated with symptom duration. Early erythematous and papulopustular changes progress to ulceration and fistula formation in prolonged disease. Although supportive in suggesting cutaneous involvement, these features are not diagnostic, and histopathological confirmation remains essential. Prospective studies are warranted to further define the clinical and histological course of cutaneous changes in IGM.
Corrigendum to "Primary bilateral breast lymphoma in an elder male patient".
Breast J · 2025 · PMID 41019570 · Full text
[This corrects the article DOI: 10.1111/tbj.13394.].
[This corrects the article DOI: 10.1111/tbj.13394.].
Corrigendum to "Analysis of Conventional Ultrasound and Contrast-Enhanced Ultrasound Features of Pseudoangiomatous Stromal Hyperplasia".
Breast J · 2025 · PMID 41019569 · Full text
[This corrects the article DOI: 10.1155/tbj/6070736.].
[This corrects the article DOI: 10.1155/tbj/6070736.].
Corrigendum to "The Quest for Outpatient Mastectomy in COVID-19 Era: Barriers and Facilitators".
Breast J · 2025 · PMID 40995536 · Full text
[This corrects the article DOI: 10.1155/2022/1863519.].
[This corrects the article DOI: 10.1155/2022/1863519.].
Morphological Assessment of Breast Lesions With Type 2 Dynamic Curves Using DWI and T2WI Based on Breast Imaging Reporting and Data System Lexicon Descriptors.
Zhang L, Zhu G, Wang K … +3 more , Zhang T, Lu L, Zhao X
Breast J · 2025 · PMID 40951334 · Full text
This study aimed to qualitatively assess the added diagnostic value of diffusion-weighted imaging (DWI) and T2-weighted imaging (T2WI), using Breast Imaging Reporting and Data System (BI-RADS) lexicon descriptors, in eva...
This study aimed to qualitatively assess the added diagnostic value of diffusion-weighted imaging (DWI) and T2-weighted imaging (T2WI), using Breast Imaging Reporting and Data System (BI-RADS) lexicon descriptors, in evaluating breast lesions with type 2 dynamic curves. We retrospectively reviewed 181 breast lesions with type 2 dynamic curves in 181 consecutive patients who underwent 3-Tesla (3-T) magnetic resonance imaging (MRI). Trained radiologists assessed the morphological features of the lesions on dynamic contrast-enhanced (DCE) MRI, DWI, and T2WI using BI-RADS lexicon descriptors and measured the apparent diffusion coefficient (ADC). Statistical analysis was performed to compare variables in lesion type groups (mass-like group vs. nonmass-like group). Diagnostic performance was evaluated using the area under the receiver operating characteristic curve (AUC) and the DeLong test, with statistical significance at < 0.05. In mass-like lesions, all morphological parameters significantly distinguished benign from malignant lesions on DCE, DWI, and T2WI (all < 0.05). ADC values also showed significant differences ( < 0.05). The combined approach (DCE + DWI + T2WI) yielded the highest AUC (0.895), significantly outperforming the individual methods (all < 0.05). In nonmass-like lesions, no parameter significantly predicted malignancy (all > 0.05). The addition of DWI and T2WI, interpreted using the BI-RADS lexicon descriptors, enhances the differential diagnosis of breast lesions with type 2 dynamic curves.
Applicability of Oncotype DX Testing in a Diverse Breast Cancer Population in Hawaii.
Xia K, Chen E, Hu R … +2 more , Pagano I, Fukui J
Breast J · 2025 · PMID 40927537 · Full text
The Oncotype DX test is standardly used for patients with early-stage, hormone-receptor-positive, HER2-negative breast cancers to determine the benefit from chemotherapy and the likelihood of distant recurrence. The rela...
The Oncotype DX test is standardly used for patients with early-stage, hormone-receptor-positive, HER2-negative breast cancers to determine the benefit from chemotherapy and the likelihood of distant recurrence. The relationship between Oncotype DX recurrence scores and race/ethnicity is still being studied. This retrospective study aims to evaluate the relationship between Oncotype DX recurrence scores, race/ethnicity, and clinicopathological factors and to support the applicability of the Oncotype DX test for a diverse breast cancer population of Hawaii. We evaluated 879 breast cancer cases diagnosed from January 2018-March 2022 within a major health system in Hawaii, 600 of which received Oncotype DX recurrence scores to provide prognostic and therapy-predictive information based on NCCN guidelines. Linear regression with both univariable (unadjusted) and multivariable (adjusted for all other variables) models was run on the 600 breast cancer cases that received Oncotype DX recurrence scores. The predictor variables were age at diagnosis, race, tumor size, ER/PR status, and histology. On multivariable analysis, we found statically significant differences in Oncotype DX recurrence scores according to age (60-69 vs. 18-49, =0.01), ER/PR status (PR-positive vs. PR-negative, < 0.0001), histology (other vs. ductal, =0.004), and tumor size (2-5 cm vs. 0-1 cm, =0.0003). We found no significant differences in Oncotype DX recurrence scores according to race/ethnicity. Our findings indicate that Oncotype DX recurrence scores are not variable according to race/ethnicity, highlighting the need for further research to understand the known disparities in breast cancer outcomes among different racial/ethnic groups. Our study supports the correlation between Oncotype DX recurrence scores and other factors and aligns with established prognostic trends for these variables in a diverse population. This study supports the applicability for the Oncotype DX test in a diverse breast cancer population of Hawaii.
Real-World Efficacy of HLX02-Based Neoadjuvant Therapy in HER2-Positive Breast Cancer: Clinical Insights and Future Directions.
Zhu Z, Wang J, Hong S … +6 more , Gao H, Liu J, Ren K, Wang S, Wang S, Sun G
Breast J · 2025 · PMID 40687942 · Full text
The efficacy of HLX02, a trastuzumab biosimilar, in combination with chemotherapy for treating metastatic breast cancer (BC) has been established as equivalent to the reference Herceptin. This study aimed to assess the t...
The efficacy of HLX02, a trastuzumab biosimilar, in combination with chemotherapy for treating metastatic breast cancer (BC) has been established as equivalent to the reference Herceptin. This study aimed to assess the treatment response of HLX02-based neoadjuvant therapy in HER2-positive BC, with a focus on HR-positive versus HR-negative subgroups. Additionally, we investigated the potential role of a CDK4/6 inhibitor in combination with anti-HER2 therapy. This retrospective study included HER2-positive BC patients who received HLX02-based neoadjuvant therapy followed by curative surgery at Anhui Provincial Cancer Hospital between March 2021 and August 2023. Pathological complete response (pCR) rates were analyzed, and subgroup analyses evaluated predictors of pCR. In vitro experiments using BT-474 and MCF-7 cell lines assessed the effects of combining CDK4/6 inhibitors with anti-HER2 therapy on cell viability and apoptosis. The study included 67 patients with a median age of 53 years. The overall pCR rate was 53.73%, with higher pCR rates observed in HR-negative patients compared to HR-positive patients (63.89% vs. 41.94%). Dual HER2 blockade with HLX02 and pertuzumab was associated with a numerically improved pCR rate (62.16%). ER expression significantly increased post-treatment, potentially indicating treatment resistance mechanisms. In vitro, the combination of CDK4/6 inhibitors with anti-HER2 therapy significantly reduced cell viability and promoted apoptosis in HR-positive, HER2-positive cell lines. HLX02 demonstrates real-world efficacy as part of neoadjuvant therapy for HER2-positive BC, especially in HR-negative patients. The lower pCR rate in HR-positive patients highlights the need for additional strategies. Combining CDK4/6 inhibitors with anti-HER2 therapy presents a promising approach for HR-positive HER2-positive patients, warranting further clinical validation.
Analysis of Conventional Ultrasound and Contrast-Enhanced Ultrasound Features of Pseudoangiomatous Stromal Hyperplasia.
Li H, Niu Q, Jia C … +8 more , Fan G, Liu L, Li G, Zou P, Wu R, Du L, Wang J, Shi Q
Breast J · 2025 · PMID 40687941 · Full text
To investigate the conventional ultrasound and contrast-enhanced ultrasound (CEUS) imaging features of pseudoangiomatous stromal hyperplasia (PASH). Retrospective analysis of clinical and imaging data of 29 patients dia...
To investigate the conventional ultrasound and contrast-enhanced ultrasound (CEUS) imaging features of pseudoangiomatous stromal hyperplasia (PASH). Retrospective analysis of clinical and imaging data of 29 patients diagnosed with PASH from June 2014 to June 2023. The median age of the patients was 39 years. Linear/cystic hypoechoic areas could be detected within the lesion in 12 cases (41.4%), and in 17 cases, the lesions had extensive conventional ultrasound findings with no significant features. The ultrasound-measured lesion diameters were smaller than those measured in surgically resected lesions, and the statistical difference was highly significant ( < 0.01). Fifteen cases underwent CEUS examination, with 7 lesions (46.7%) demonstrating uniform enhancement and 8 lesions (53.3%) exhibiting nonuniform enhancement. Within the enhanced regions, perfusion defects were observed, all of which were of the patchy type. The areas of patchy perfusion defects corresponded to the linear/cystic hypoechoic regions observed in the conventional sonographic images of the lesions. The use of CEUS provided additional diagnostic clarity compared with conventional ultrasound. Specifically, the specificity for identifying PASH lesions increased from 35.7% with conventional ultrasound to 64.3% with CEUS, highlighting the value of CEUS in enhancing the diagnostic accuracy for PASH lesions. This study suggests that linear/cystic hypoechoic areas on sonography may serve as crucial clues for the ultrasound diagnosis of PASH. The presence of diffuse patchy perfusion defects in CEUS contributes to the accurate diagnosis of PASH.
Application of Microwave Ablation Combined With Chai Hu Qing Gan Tang in the Treatment of Idiopathic Granulomatous Mastitis.
Li H, Li B, Chen H … +3 more , Liu X, Wang H, Zhang G
Breast J · 2025 · PMID 40661927 · Full text
To investigate the efficacy of microwave ablation (MVA) combined with Chai Hu Qing Gan Tang (CHQGT) for idiopathic granulomatous mastitis (IGM). 480 patients were divided into the CHQGT combination group (CHQGT + MVA),...
To investigate the efficacy of microwave ablation (MVA) combined with Chai Hu Qing Gan Tang (CHQGT) for idiopathic granulomatous mastitis (IGM). 480 patients were divided into the CHQGT combination group (CHQGT + MVA), corticosteroid combination group (glucocorticoids + MVA) and control group (glucocorticoids), with 160 cases in each group. Data on patient information, treatment effects, adverse effects and breast appearance were collected. Network pharmacology was used to identify the effective active ingredients and target information of CHQGT. The Gene Cards database was used to obtain the relevant targets of IGM, and the drug-component-common target relationship network was constructed using Cytoscape 3.9.1 software. All treatment groups showed significant differences in Visual Analog Scale score, Hamilton Depression Rating Scale score, Hamilton Anxiety Rating Scale, mass size and the total effective rate ( < 0.001). There was a statistically significant difference in the rate of excellent breast shape between the three groups after treatment ( < 0.001), with the rate higher in the CHQGT liver decoction combined with glucocorticoids treatment group compared with the control group. There was a statistically significant difference in the incidence of adverse reactions and recurrence rate between the three groups within 2 years after treatment ( < 0.001), with the incidence of adverse reactions and recurrence rate higher in the control group than in the glucocorticoid combination and CHQGT decoction combination groups. Network pharmacology identified 199 active ingredients and 23 drug-disease targets of CHQGT. The molecular docking results showed that the main active components screened had good binding activity with their corresponding target proteins. The combination of CHQGT and MWA is comparable in overall therapeutic efficacy to the combination of glucocorticoids and MWA. However, the CHQGT and MWA combination is superior in reducing lump size, alleviating patient pain and accelerating recovery.
Underserved Patient Populations With Metastatic Breast Cancer: A Review of Progress and Remaining Challenges.
Cardoso F, Wuerstlein R, Aruga T … +9 more , Haidinger R, Lambertini M, Benjamin C, Valentí EL, Criscitiello C, Aapro M, Grana G, Gentry SS, Vrdoljak E
Breast J · 2025 · PMID 40625591 · Full text
Breast cancer presents a significant risk to public health and is the primary cause of cancer-related death in women. Awareness of metastatic breast cancer (mBC) continues to increase, and advances have been made; howeve...
Breast cancer presents a significant risk to public health and is the primary cause of cancer-related death in women. Awareness of metastatic breast cancer (mBC) continues to increase, and advances have been made; however, challenges remain for many patient populations that do not receive equal opportunities along the treatment pathway. The Underserved Patient Population (UPP) Coalition Task Force, a group of international experts in mBC, held meetings between 2022 and 2023 to prioritise the needs of UPPs and propose solutions. The key unmet needs identified included the following: delayed diagnosis of mBC due to difficulties in the presentation of patients to the healthcare system and a lack of primary care physician and non-breast cancer specialist understanding of the signs and symptoms of mBC; difficulty navigating the mBC patient pathway due to suboptimal use of multidisciplinary care and limited communication between HCPs; unequal access to the most appropriate mBC treatment options and supportive therapy due to the unconscious bias of HCPs, and direct and indirect financial toxicity for patients; and negative impact on QoL resulting from the limited uptake of shared decision-making, low prioritisation of patient preferences and a lack of personalised care. This paper aims to shine light on initiatives supporting underserved patients with mBC, illustrate the remaining gaps in care and call upon the global community to change how care is delivered to UPPs.
Clinical Outcomes of CDK4/6 Inhibitor Therapy in HR+/HER2- Metastatic Breast Cancer: A Multicenter Comparison of HER2-Low and HER2-Zero Subgroups.
Ozcan E, Gokmen I, Akgul F … +5 more , Kahvecioglu FA, Celebi A, Kostek O, Hacıbekiroglu I, Erdogan B
Breast J · 2025 · PMID 40620732 · Full text
The clinical impact of HER2-low status on the efficacy of cyclin-dependent kinase 4/6 inhibitor (CDK4/6i). Therapy in patients with hormone receptor-positive (HR+), HER2-negative metastatic breast cancer (MBC) remains un...
The clinical impact of HER2-low status on the efficacy of cyclin-dependent kinase 4/6 inhibitor (CDK4/6i). Therapy in patients with hormone receptor-positive (HR+), HER2-negative metastatic breast cancer (MBC) remains unclear. We conducted a multicenter, retrospective analysis including 212 female patients with HR+/HER2-MBC treated with CDK4/6is between 2018 and 2022. Patients were classified as HER2-zero or HER2-low based on immunohistochemistry results. Progression-free survival (PFS), objective response rate (ORR), and disease control rate (DCR) were compared between the two groups. Median PFS was 16.0 months in the HER2-low group and 13.9 months in the HER2-zero group (=0.40). In first-line therapy, PFS was numerically longer in the HER2-low group (18.6 vs. 14.9 months; =0.26) although this was not statistically significant. ORR was 71.4% in HER2-low and 62% in HER2-zero patients, and DCR was 86.6% and 82%, respectively (both > 0.05). Subgroup analyses showed that within the HER2-low group, patients with ≥ 2 metastatic sites had significantly shorter PFS compared with those with a single site (14.1 vs. 20.2 months; =0.02), and the presence of visceral metastases was associated with poorer PFS (=0.003). Overall survival (OS) data were immature, with only 24.6% of the patients deceased at the time of analysis. HER2 status did not significantly impact treatment outcomes with CDK4/6i in HR+/HER2-negative MBC patients. However, subgroup analyses indicated that metastatic burden, particularly the number of metastatic sites and the presence of visceral disease, may adversely influence PFS. These findings highlight the need for further validation in larger prospective studies.
Extratumoral Signs of Malignant Nonspiculate and Noncalcified Masses on Mammography: Are They Associated With Prognostic Factors in Breast Cancer?
Xu Y, Yang X, Wang F … +4 more , Wu D, Sun J, Meng H, Zhang X
Breast J · 2025 · PMID 40599582 · Full text
To investigate the association between mammographic extratumoral signs, specifically their subclassifications, of nonspiculate and noncalcified masses (NSNCMs) and prognostic factors in breast cancer. This retrospective...
To investigate the association between mammographic extratumoral signs, specifically their subclassifications, of nonspiculate and noncalcified masses (NSNCMs) and prognostic factors in breast cancer. This retrospective study analyzed imaging and pathological data from 374 patients, categorizing extratumoral signs into structural abnormalities (parenchymal and trabecular) and halo, while also undergoing subclassification. The focus prognostic factors were achieved through screening. Then, univariate and multivariate analyses were performed. Correlation analysis was also employed to determine the relationship between subclassifications and prognostic factors. Lymphovascular invasion (LVI), Ki-67 levels, and stromal tumor-infiltrating lymphocytes (sTIL) levels were identified as the focus prognostic factors. Among tumor signs, only tumor margin was associated with sTIL levels. Extratumoral trabecular signs exhibited a significant correlation with LVI (OR = 2.5, =0.007) and Ki-67 levels (OR = 1.23, =0.001). Specifically, the parallel sign showed a positive correlation with LVI (=0.009, = 0.134), while the reticular sign displayed a positive correlation with Ki-67 levels (=0.009, = 0.134). Extratumoral parenchymal signs were found to be an independent predictor for sTIL levels (OR = 0.64, < 0.001), with a negative correlation observed between the contraction sign and sTIL levels ( < 0.001, = -0.185), as well as between the atrophy sign and sTIL levels (=0.046, = -0.103). Specific extratumoral structural abnormalities of mammographic malignant NSNCMs showed a significant correlation with prognostic factors in breast cancer, warranting increased attention in research and clinical practice.
Efficacy of Presurgical Short-Term Endocrine Therapy During the Waiting Period for Surgery in Postmenopausal Hormone Receptor-Positive Breast Cancer.
Maeda Y, Sato A, Matsumoto A … +2 more , Ikeda T, Jinno H
Breast J · 2025 · PMID 40443563 · Full text
Although presurgical endocrine therapy has been used to enhance the rate of breast cancer conservation, its prognostic relevance is unknown. The search for a valid prognostic factor equivalent to pathological complete re...
Although presurgical endocrine therapy has been used to enhance the rate of breast cancer conservation, its prognostic relevance is unknown. The search for a valid prognostic factor equivalent to pathological complete response in presurgical chemotherapy remains a challenge in presurgical endocrine therapy. This study investigated the efficacy of presurgical short-term endocrine therapy (preSTE) and assessed prognostic factors, including the preoperative endocrine prognostic index (PEPI) score. From October 2012 to November 2021, 269 postmenopausal women diagnosed with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 negative breast cancer underwent endocrine therapy with a nonsteroidal aromatase inhibitor during the presurgical waiting period. The primary endpoint was to assess the changes in tumor size using ultrasonography, and Ki67 expression levels before and after preSTE. The secondary endpoint was the prognosis of patients categorized using the PEPI score. The median age of patients was 68 years (range, 41-89 years). The median tumor size was 1.65 cm (range, 0.4-7.5 cm). The average pretreatment Ki67 expression level was 10% (range, 0%-90%). The median duration of endocrine therapy was 39 days (range, 2-88 days). Tumor diameter and Ki67 expression levels were significantly decreased to 1.43 cm (range, 0.45-5.83 cm) and 3.0% (range, 0%-85%) after preSTE, respectively. After the median observation period of 928 days, patients with PEPI scores ≥ 4 showed worse disease-free survival compared with those with lower PEPI scores. In terms of mortality, patients with PEPI score ≥ 4 had worse overall survival than did patients with lower PEPI scores. Endocrine therapy during the waiting period for surgery might be effective in reducing tumor size, and the Ki67 expression level and PEPI score might be useful in predicting the prognosis of patients with postmenopausal HR+ breast cancer.
Exploring New Frontiers: Alternative Breast Cancer Treatments Through Glycocalyx Research.
Gorodetska I, Samusieva A, Lahuta T … +3 more , Ponomarova O, Socha O, Kozeretska I
Breast J · 2025 · PMID 40443562 · Full text
Breast cancer (BC) treatment is developing toward more precise and personalized care through the approval of different comprehensive approaches. Clinical practice emphasizes significant patient-to-patient variability in...
Breast cancer (BC) treatment is developing toward more precise and personalized care through the approval of different comprehensive approaches. Clinical practice emphasizes significant patient-to-patient variability in treatment response among patients, even those with similar clinical and biological profiles. Recent studies have demonstrated that the glycocalyx is an essential organelle that plays an important role in many cellular processes and can be a promising target for treatment. The glycocalyx of cancer cells is a key component influencing the interaction between the tumor and the immune system. Glycan modifications attached to glycoproteins and glycolipids are a common characteristic of the transition to malignancy. We review how the specific structure and function of the glycocalyx are regulated at the molecular level, contribute to immune evasion, and can be overcome by using both traditional drugs and combination therapies, as well as drugs not previously used in standard cancer treatments, to address treatment resistance associated with glycocalyx alterations. ClinicalTrials.gov identifier: NCT00770354, NCT00925548, NCT01731587, NCT00088413, NCT00179309, NCT00986609, NCT05812326, NCT04020575, NCT05239143, NCT01279603, and NCT03562637.
Comparative Efficacy of Neoadjuvant Endocrine Therapy, Neoadjuvant Chemotherapy, and Neoadjuvant Chemo-Endocrine Therapy in Estrogen Receptor-Positive Breast Cancer Patients: A Meta-Analysis.
Yuan Y, Cui N, Xu Z … +3 more , Cui C, Zhou Z, Ma Z
Breast J · 2025 · PMID 40405908 · Full text
Neoadjuvant therapy before surgery offers varying benefits as a well-established treatment option for breast cancer. This study specifically evaluated the effectiveness of neoadjuvant endocrine therapy (NET), neoadjuvant...
Neoadjuvant therapy before surgery offers varying benefits as a well-established treatment option for breast cancer. This study specifically evaluated the effectiveness of neoadjuvant endocrine therapy (NET), neoadjuvant chemotherapy (NCT), and neoadjuvant chemo-endocrine therapy (NCET) in patients with estrogen receptor (ER)-positive breast cancer. This meta-analysis was conducted and reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Electronic searching was conducted to retrieve articles from databases including PubMed, Cochrane Library, EMBASE, CNKI, and Wanfang. The primary outcome measured by odds ratios (ORs) with 95% confidence intervals (CIs) focused on assessing pooled effect sizes. Random-effects or fixed-effect models were conducted according to the existence of statistical heterogeneity. A total of 15 eligible articles were included in the analysis. The results indicated clinical response (CR) (OR = 0.54; 95% CI = 0.41 to 0.73; = 39.6%) and clinical complete response (cCR) (OR = 0.31; 95% CI = 0.12 to 0.85; = 68.0%) after NET was significantly higher than NCT. However, no significant difference was shown in pathological complete response (pCR) (OR = 0.49; 95% CI = 0.23 to 1.04; = 0.0%) and breast-conserving surgery (BCS) (OR = 0.49; 95% CI = 0.23 to 1.04; = 0.0%). The combined paradigm of NCET presented no significant improvement compared with monotherapy of NET or NCT. Overall, both NET and NCT are effective neoadjuvant treatment options for patients with ER+ breast cancer. More explicit clinical decision indicators need to be further clarified. And NCET does not offer additional benefits over NET or NCT in patients with ER+ breast cancer.
Pretreatment Axillary Nodal Volume as a Prognostic Factor for Breast Cancer.
Jeong Y, Kim JH, Kim SS … +7 more , Jung J, Joo JH, Kim HJ, Kim HH, Cha JH, Shin HJ, Ahn SD
Breast J · 2025 · PMID 40313914 · Full text
We evaluated the prognostic value of pretreatment axillary nodal volume in breast cancer patients treated with neoadjuvant systemic therapy. We retrospectively reviewed 302 breast cancer patients with biopsy-proven axil...
We evaluated the prognostic value of pretreatment axillary nodal volume in breast cancer patients treated with neoadjuvant systemic therapy. We retrospectively reviewed 302 breast cancer patients with biopsy-proven axillary LN involvement who received neoadjuvant systemic therapy. Axillary nodal volumes were obtained from pretreatment magnetic resonance imaging. Univariate and multivariate analyses for disease-free survival (DFS) and overall survival (OS) rates were conducted. The median follow-up period was 57.0 months, and 5-year DFS and OS rates were 81.6% and 91.9%, respectively. Pretreatment axillary nodal volume ranged from 0.2 mL to 134.2 mL, and the first tertile (2.6 mL) and fifth quintile (12.0 mL) were chosen as the optimal cutoff points for survival outcomes. In the multivariate analysis, nodal volume (< 2.6 mL vs. 2.6-12.0 mL vs. ≥ 12.0 mL) was a significant prognostic factor for DFS (5-year DFS, 90.1% vs. 79.6% vs. 72.2%) and OS (5-year OS, 97.9% vs. 90.9% vs. 84.2%), whereas the stage was not. In breast cancer patients treated with neoadjuvant systemic therapy, larger pretreatment axillary nodal volume was associated with poor survival outcomes.
Development of a Prognostic Score in Patients With Advanced Breast Cancer Treated for Meningeal Carcinomatosis.
Narjoux G, Mainguené J, Guilhaume MN … +7 more , Brenet O, Borcoman E, Escalup L, Salaun H, Moreau P, Bouyer AS, Cottu P
Breast J · 2025 · PMID 40224951 · Full text
Meningeal carcinomatosis (MC) has a dismal prognosis in patients with breast cancer and requires invasive therapies. The aim of the present retrospective study was to determine a prognostic score for overall survival (OS...
Meningeal carcinomatosis (MC) has a dismal prognosis in patients with breast cancer and requires invasive therapies. The aim of the present retrospective study was to determine a prognostic score for overall survival (OS) in patients with breast cancer and treated for MC. The data of 109 patients with proven breast cancer MC treated with at least one intrathecal (IT) injection of methotrexate or thiotepa at Institut Curie were retrospectively recorded from 2011 to 2019. We developed prognostic clinical scores for OS and 24-week survival. The diagnosis and evaluation of MC were based on a combination of clinical, imaging, and laboratory studies. Three significant prognostic factors for OS were identified. Clinical response or stabilization after one month of IT therapy had a favorable independent prognostic value for both OS and 24-week survival. Additionally, a baseline CSF Cyfra 21-1 concentration lower than 79 ng/mL in the cerebrospinal fluid (CSF) and the absence of 1-month CSF malignant cells had borderline favorable independent prognostic value for OS and 24-week survival, respectively. We constructed 2-class and 3-class prognostic scores for each outcome, identifying a population with a very poor prognosis. To our knowledge, this is the first study to develop a response-based prognosis score for patients with breast cancer-related MC. This one-month prognostic score may help to determine which patient could actually benefit from prolonged IT therapy.
Identification of the Molecular Subtype and Prognostic Characteristics of Breast Cancer Based on Tumor-Infiltrating Regulatory T Cells.
Ma J, Hu G, Kuang L … +1 more , Zhu Z
Breast J · 2025 · PMID 40224950 · Full text
T regulatory cells (Tregs) are essential for preserving immune tolerance. They are present in large numbers in many tumors, hindering potentially beneficial antitumor responses. However, their predictive significance for...
T regulatory cells (Tregs) are essential for preserving immune tolerance. They are present in large numbers in many tumors, hindering potentially beneficial antitumor responses. However, their predictive significance for breast cancer (BC) remains ambiguous. This study aimed to explore genes associated with Tregs and develop a prognostic signature associated with Tregs. The gene expression and clinical data on BC were obtained from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. The integration of CIBERSORT and weighted correlation network analysis (WGCNA) algorithms was utilized to identify modules associated with Tregs. The consensus cluster algorithm was utilized to create molecular subtypes determined by genes associated with Tregs. Then, a prognostic signature associated with Tregs was constructed and its relationship to tumor immunity and the prognosis was evaluated. The blue module genes exhibited the most significant correlation with Tregs, and 1080 genes related to Tregs were acquired. A total of 93 genes from the TCGA dataset were found to have a significant impact on patient prognosis. Samples from BC were categorized into two clusters by consensus cluster analysis. The overall survival, immune checkpoint genes, molecular subtype, and biological behaviors varied significantly between these two subtypes. A 10-gene signature developed from differentially expressed genes between two subtypes demonstrated consistent prognostic accuracy in both TCGA and GEO datasets. It functioned as a standalone prognostic marker for individuals with BC. In addition, patients with low risk are more inclined to exhibit increased immune cell infiltration, TME score, and tumor mutation burden (TMB). Meanwhile, Individuals classified within the low-risk group showed better responses to immunotherapies compared to their counterparts in the high-risk group. The prognostic model derived from Tregs-related genes could aid in assessing the prognosis, guiding personalized treatment, and potentially enhancing the clinical outcomes for patients with BC.
Rare Histological Types of Breast Cancer: A Single-Center Experience.
Sağdıç MF, Özaslan C
Breast J · 2025 · PMID 40224949 · Full text
Breast carcinoma is divided into at least 21 separate histologies, according to the 2019 World Health Organization (WHO) classification. The present study is dedicated to a 5% or rarer group of all breast cancer cases....
Breast carcinoma is divided into at least 21 separate histologies, according to the 2019 World Health Organization (WHO) classification. The present study is dedicated to a 5% or rarer group of all breast cancer cases. In this study, we retrospectively considered the data of 4550 patients operated on for breast carcinoma at the Ankara Oncology Training and Research Hospital of the University of Health Sciences between January 2018 and February 2024. Of those cases, 401 were discovered to have rare breast cancer types. We also explored the cases by clinicopathological features, overall survival (OS), and disease-free survival (DFS). Our findings revealed a total of 10 rare breast cancer types in patients explored: mucinous carcinoma, micropapillary carcinoma, papillary group carcinomas, metaplastic carcinoma, neuroendocrine carcinoma, tubular carcinoma, cribriform carcinoma, apocrine carcinoma, acinic cell carcinoma, and secretory carcinoma. While mucinous, tubular, cribriform, papillary group carcinomas, micropapillary, and secretory carcinomas are described as types associated with good prognosis, metaplastic, neuroendocrine, apocrine, and carcinomas are described as types associated with relatively poor prognosis. Scrutinizing the clinicopathological features of rare breast cancer types altogether may be the distinct contribution of this paper to the relevant literature and future research.
About
- Frequency
- Sun
- Papers found
- 200
- RSS feed
- Subscribe